Amgen Inc. Cost of Goods Sold (Deprecated 2018-01-31)
Amgen Inc. (AMGN) reported Cost of Goods Sold (Deprecated 2018-01-31) of $944.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-25.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-04-25
- Amgen Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $944.00M, a 5.22% decline year-over-year.
- Amgen Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $1.06B, a 0.75% decline year-over-year.
- Amgen Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $990.00M, a 3.60% decline year-over-year.
- Amgen Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $1.02B, a 2.48% decline year-over-year.
- Amgen Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $4.07B, a 2.23% decline from fiscal 2016.
- Amgen Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $4.16B, a 1.54% decline from fiscal 2015.
- Amgen Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $4.23B, a 4.41% decline from fiscal 2014.
- Amgen Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $4.42B.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $944.00M 10-Q · filed 2018-04-25 | $2.00B derived: sum of 2 quarters · filed 2018-04-25 | $2.99B derived: sum of 3 quarters · filed 2018-04-25 | $4.02B derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-12-31 | $1.06B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $2.05B derived: sum of 2 quarters · filed 2018-02-13 | $3.07B derived: sum of 3 quarters · filed 2018-02-13 | $4.07B 10-K · filed 2018-02-13 |
| 2017-09-30 | $990.00M 10-Q · filed 2017-10-26 | $2.01B derived: sum of 2 quarters · filed 2017-10-26 | $3.01B 10-Q · filed 2017-10-26 | $4.08B derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-06-30 | $1.02B 10-Q · filed 2017-07-26 | $2.02B 10-Q · filed 2017-07-26 | $3.09B derived: sum of 3 quarters · filed 2018-04-25 | $4.11B derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-03-31 | $996.00M 10-Q · filed 2018-04-25 | $2.06B derived: sum of 2 quarters · filed 2018-04-25 | $3.09B derived: sum of 3 quarters · filed 2018-04-25 | $4.14B derived: sum of 4 quarters · filed 2018-04-25 |
| 2016-12-31 | $1.07B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $2.09B derived: sum of 2 quarters · filed 2018-02-13 | $3.14B derived: sum of 3 quarters · filed 2018-02-13 | $4.16B 10-K · filed 2018-02-13 |
| 2016-09-30 | $1.03B 10-Q · filed 2017-10-26 | $2.08B derived: sum of 2 quarters · filed 2017-10-26 | $3.10B 10-Q · filed 2017-10-26 | $4.17B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $1.05B 10-Q · filed 2017-07-26 | $2.07B 10-Q · filed 2017-07-26 | $3.14B derived: sum of 3 quarters · filed 2018-02-13 | $4.17B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $1.02B 10-Q · filed 2017-04-27 | $2.09B derived: sum of 2 quarters · filed 2018-02-13 | $3.12B derived: sum of 3 quarters · filed 2018-02-13 | $4.21B derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $1.07B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $2.10B derived: sum of 2 quarters · filed 2018-02-13 | $3.19B derived: sum of 3 quarters · filed 2018-02-13 | $4.23B 10-K · filed 2018-02-13 |
| 2015-09-30 | $1.03B 10-Q · filed 2016-10-28 | $2.12B derived: sum of 2 quarters · filed 2016-10-28 | $3.16B 10-Q · filed 2016-10-28 | $4.34B derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $1.09B 10-Q · filed 2016-07-29 | $2.12B 10-Q · filed 2016-07-29 | $3.31B derived: sum of 3 quarters · filed 2017-02-14 | $4.37B derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $1.03B 10-Q · filed 2016-05-02 | $2.22B derived: sum of 2 quarters · filed 2017-02-14 | $3.28B derived: sum of 3 quarters · filed 2017-02-14 | $4.37B derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $1.18B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $2.25B derived: sum of 2 quarters · filed 2017-02-14 | $3.33B derived: sum of 3 quarters · filed 2017-02-14 | $4.42B 10-K · filed 2017-02-14 |
| 2014-09-30 | $1.07B 10-Q · filed 2015-11-02 | $2.15B derived: sum of 2 quarters · filed 2015-11-02 | $3.24B 10-Q · filed 2015-11-02 | $4.27B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-06-30 | $1.08B 10-Q · filed 2015-08-05 | $2.17B 10-Q · filed 2015-08-05 | $3.20B derived: sum of 3 quarters · filed 2016-10-31 | $3.99B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-03-31 | $1.09B 10-Q · filed 2015-04-27 | $2.12B derived: sum of 2 quarters · filed 2016-10-31 | $2.91B derived: sum of 3 quarters · filed 2016-10-31 | $3.69B derived: sum of 4 quarters · filed 2016-10-31 |
| 2013-12-31 | $1.03B derived: 8-K 12 month − 10-Q 9 month · filed 2016-10-31 | $1.82B derived: sum of 2 quarters · filed 2016-10-31 | $2.60B derived: sum of 3 quarters · filed 2016-10-31 | $3.35B 8-K · filed 2016-10-31 |
| 2013-09-30 | $788.00M 10-Q · filed 2014-10-29 | $1.57B derived: sum of 2 quarters · filed 2014-10-29 | $2.32B 10-Q · filed 2014-10-29 | $3.24B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $785.00M 10-Q · filed 2014-08-05 | $1.53B 10-Q · filed 2014-08-05 | $2.45B derived: sum of 3 quarters · filed 2015-02-19 | $3.23B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | $744.00M 10-Q · filed 2014-04-30 | $1.67B derived: sum of 2 quarters · filed 2015-02-19 | $2.44B derived: sum of 3 quarters · filed 2015-02-19 | $3.19B derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $922.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $1.70B derived: sum of 2 quarters · filed 2015-02-19 | $2.45B derived: sum of 3 quarters · filed 2015-02-19 | $3.20B 10-K · filed 2015-02-19 |
| 2012-09-30 | $775.00M 10-Q · filed 2013-10-29 | $1.53B derived: sum of 2 quarters · filed 2013-10-29 | $2.28B 10-Q · filed 2013-10-29 | |
| 2012-06-30 | $752.00M 10-Q · filed 2013-08-06 | $1.50B 10-Q · filed 2013-08-06 | ||
| 2012-03-31 | $750.00M 10-Q · filed 2013-05-03 | |||
| 2011-12-31 | $2.71B 10-K · filed 2014-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |